|
|
|
08.10.26 - 18:00
|
SpineGuard Announces Its Q3 Revenue (Business Wire)
|
|
|
A +22% increase in the total number of units sold during the period
Sales growing +25% outside the United States
A return to volume growth in the United States and confirmation of operational synergies with Omnia Medical
PARIS--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announces its third quarter 2026 revenue.
Pierre Jérôme, Co-founder, Chairman and CEO of SpineGuard, stated:
“The third quarter marks an important milestone for SpineGuard with a +22% increase in the number of units sold worldwide, driven by strong momentum in the various geographic regions where we operate through our commercial partners.
In the United States, unit sales are rising again, driven by orders from Omnia Medical, which are becoming more consistent and substantial. The commercial synergies we sought by transferring the assets o...
|
|
|
09.09.26 - 18:06
|
SpineGuard Reports 2026 Half-Year Results (Business Wire)
|
|
|
An interactive webinar will be held in French on Thursday, September 10, 2026, at 2:30 pm
Register HerePARIS--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announces its financial results for the first half of the fiscal year ended June 30, 2026, as approved by the Board of Directors held on September 9, 2026.
Pierre Jérôme, Co-founder, Chairman and CEO of SpineGuard, stated: “Our half-year financial results, which were down compared to the first half of 2025, are attributable to the recognition of all costs related to the sale of our U.S. subsidiary's assets to our partner Omnia Medical, the deferral of the proceeds from this sale through 2032, an inventory effect related to the transition, and a shift in business model. However, this in no way calls into question the soundness of this transaction or our g...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.07.26 - 18:03
|
SpineGuard Announces its H1 2026 Revenue (Business Wire)
|
|
|
PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 - ALSGD), an innovative company that deploys its DSG® (Dynamic Surgical Guidance) local conductivity sensing technology to secure and streamline the placement of bone implants, today announced its first half 2026 revenue.
Pierre Jérôme, Co-founder, Chairman and CEO of SpineGuard, stated:
“Revenue for the first half of the year is in line with our roadmap. Our DSG technology is increasingly establishing itself as the efficient and reliable alternative to navigation systems and robots, whose cost and associated constraints limit their adoption by practitioners and hospitals.
In the United States, the transitional effects related to the sale of SpineGuard Inc. and the shift to a distribution model were anticipated. These effects are accompanied by an improvement in our profitability per unit sold and should enable a gradual ramp-up in sales volumes of Pediguard devices thanks to commercial synergies with Omnia Medical. Pr...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.01.26 - 18:06
|
SpineGuard Reports Its Full-year 2025 Revenue (Business Wire)
|
|
|
PARIS & BOULDER, Colo.--(BUSINESS WIRE)--Regulatory News:
SpineGuard (FR0011464452 – ALSGD), an innovative company that deploys its digital surgical guidance (DSG®) technology, which measures the electrical conductivity of tissues in real time at the local level to secure and simplify the placement of bone implants, today announced its revenue for the fiscal year ended December 31, 2025.
Pierre Jérôme, Chairman, CEO and co-founder of SpineGuard, said: " The actions taken in 2025 to adapt our cost structure, particularly in the United States, significantly improved our operating performance, while having a temporary downward impact on our revenue. The growth recorded in Europe and Asia, as well as the sequential increase in our overall revenue in the fourth quarter, demonstrate the resilience of our model. The settlement of our main debt is a key milestone that will facilitate the finalization of the sale of our US subsidiary to Omnia Medical, our US partner, which is set to launch its new sacroi...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
